In this month’s PME, out this week in both its print and online forms, we speak to Allergan’s Paul Navarre and Paul Boland for our lead interview and hear how they’re creating a culture of growth.
The June issue also takes a look at the Sunshine Act and finds that the US legislation’s implications are anything but clear for European pharma, and there are features on diabetes marketing, communications and commercial relationships in China and the consumerisation of mHealth.
There’s also a look at the emergence of cancer immunotherapies in our regular pipeline feature and an introduction to our forthcoming collaboration with European healthcare communications group the HCC.
• Read the June 2014 issue of PME in full online
Taking aim at digital disruption to pharma the May issue of PME was out this week in both its print and online incarnations.
The issue also featured an exclusive interview with AstraZeneca’s VP of oncology Susan Galbraith who talked about the company’s pipeline prospects – a topic that shortly after the interview was conducted took on added significance. Read the rest of this entry »
Closing an issue of the magazine the day your youngest son wakes at 4am with growing pains and can’t get back to sleep is not necessarily to be recommended, but we got there in the end and put together another good looking issue.
This month’s PME (Pharmaceutical Market Europe) features an exclusive interview with MSD’s president, Europe and Canada Bruno Strigini on pharma’s new market reality.
We also spoke with Janssen’s company group chairman responsible for the EMEA region Jane Griffiths and EFPIA’s chairman Richard Bergstrom on how they would like the industry to be seen. Read the rest of this entry »